2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
01/08/18Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliates, further strengthening Editas’ guide RNA chemistry capabilities and intellectual property Provides updates on advancements in ocular and engineered cell medicine programs CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NE... 
 Printer Friendly Version
01/03/18Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco, CA. A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas... 
 Printer Friendly Version
Print Page    E-mail Page    RSS    E-mail Alerts